TY - JOUR
T1 - B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts
AU - Goetze, Jens Peter
AU - Rehfeld, Jens F
AU - Videbaek, Regitze
AU - Friis-Hansen, Lennart
AU - Kastrup, Jens
PY - 2005/1
Y1 - 2005/1
N2 - BACKGROUND: Plasma concentrations of B-type natriuretic peptide (BNP-32) and its precursor (proBNP) are increased in chronic heart failure. Accordingly, BNP-32 and proBNP are both being implemented as clinical markers.AIM: To determine the molar relation of BNP-32 and proBNP in different cardiovascular regions.METHODS AND RESULTS: Blood samples were obtained from different cardiovascular regions during right heart catheterization in heart failure patients, and from normal subjects. Plasma BNP-32 and proBNP concentrations were measured using sequence-specific radioimmunoassays. Patients with severe left ventricular dysfunction (n=21) displayed increased peripheral plasma concentrations of both BNP-32 (four-fold, P=0.0008) and proBNP (seven-fold, P=0.0002) compared with normal subjects. Moreover, the peripheral concentrations were highly correlated with the corresponding concentrations in the coronary sinus (BNP-32: r=0.97, P<0.0001; proBNP: r=0.94, P<0.0001). Despite comparable peripheral concentrations of BNP-32 and proBNP, the BNP-32 concentration was higher than the proBNP concentration in the coronary sinus (median 126 pmol/l (21-993) vs. 103 pmol/l (16-691), P=0.035).CONCLUSIONS: The BNP-32 and proBNP concentrations are closely related in venous cardiac blood. The findings suggest an overall constitutive secretion of processed proBNP, i.e. an N-terminal precursor fragment and BNP-32, in chronic heart failure.
AB - BACKGROUND: Plasma concentrations of B-type natriuretic peptide (BNP-32) and its precursor (proBNP) are increased in chronic heart failure. Accordingly, BNP-32 and proBNP are both being implemented as clinical markers.AIM: To determine the molar relation of BNP-32 and proBNP in different cardiovascular regions.METHODS AND RESULTS: Blood samples were obtained from different cardiovascular regions during right heart catheterization in heart failure patients, and from normal subjects. Plasma BNP-32 and proBNP concentrations were measured using sequence-specific radioimmunoassays. Patients with severe left ventricular dysfunction (n=21) displayed increased peripheral plasma concentrations of both BNP-32 (four-fold, P=0.0008) and proBNP (seven-fold, P=0.0002) compared with normal subjects. Moreover, the peripheral concentrations were highly correlated with the corresponding concentrations in the coronary sinus (BNP-32: r=0.97, P<0.0001; proBNP: r=0.94, P<0.0001). Despite comparable peripheral concentrations of BNP-32 and proBNP, the BNP-32 concentration was higher than the proBNP concentration in the coronary sinus (median 126 pmol/l (21-993) vs. 103 pmol/l (16-691), P=0.035).CONCLUSIONS: The BNP-32 and proBNP concentrations are closely related in venous cardiac blood. The findings suggest an overall constitutive secretion of processed proBNP, i.e. an N-terminal precursor fragment and BNP-32, in chronic heart failure.
KW - Adult
KW - Aged
KW - Cardiac Catheterization
KW - Case-Control Studies
KW - Female
KW - Heart Atria/metabolism
KW - Heart Failure/blood
KW - Heart Ventricles/metabolism
KW - Humans
KW - Male
KW - Middle Aged
KW - Natriuretic Peptide, Brain/blood
KW - Nerve Tissue Proteins/blood
KW - Peptide Fragments/blood
KW - Pulmonary Artery/metabolism
KW - Severity of Illness Index
KW - Vena Cava, Inferior/metabolism
U2 - 10.1016/j.ejheart.2004.04.012
DO - 10.1016/j.ejheart.2004.04.012
M3 - Journal article
C2 - 15642534
SN - 1388-9842
VL - 7
SP - 69
EP - 74
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 1
ER -